STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Boudadi, Karim
Suzman, Daniel L.
Luber, Brandon
Wang, Hao
Silberstein, John L.
Taylor, Maritza N.
Sullivan, Rana
Dowling, Donna
Harb, Rana
Dittamore, Ryan Vance
Meeker, Alan
Luo, Jun
Drake, Charles G.
Antonarakis, Emmanuel S.
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[4] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Marriottsville, MD USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Epic Sci, San Diego, CA USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS5089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5089
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [32] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Brown, Myles
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Phase III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC): A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - AUO Study AP 118/21
    Rexer, Heidrun
    Boegemann, Martin
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (03) : 226 - 228
  • [34] PHASE 2 TRIAL OF A DNA VACCINE WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    McNeel, Douglas
    Eickhoff, Jens
    Wargowski, Ellen
    Johnson, Laura
    Kyriakopoulos, Christos
    Emamekhoo, Hamid
    Lang, Joshua
    Brennan, Mary Jane
    Liu, Glenn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A377 - A377
  • [35] Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).
    Chi, Kim N.
    Mukherjee, Som
    Saad, Fred
    Winquist, Eric
    Ong, Michael
    Kolinsky, Michael Paul
    Sacher, Adrian G.
    Ferrario, Cristiano
    Salim, Muhammad
    Macfarlane, Robyn Jane
    Iqbal, Nayyer
    Hotte, Sebastien J.
    Annala, Matti
    Petrovic, Jelena
    Tu, Dongsheng
    Rushton, Moira Katherine
    Badillo, Francisco Emilio Vera
    Smoragiewicz, Martin
    Wyatt, Alexander William
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2
    Ostergren, Peter B.
    Murtola, Teemu J.
    Fode, Mikkel
    EUROPEAN UROLOGY, 2019, 75 (06) : 938 - 939
  • [37] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).
    McKay, Rana R.
    Radke, Marc R.
    Shyr, Yu
    Zhao Shilin
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo Lucky N.
    Vaishampayan, Ulka N.
    Zhang Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Huang Ying
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, Percy S.
    Petrylak, Daniel Peter
    Swisher, Elizabeth M.
    Kim, Joseph W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [39] Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).
    Pahuja, Shalu
    Appleman, Leonard Joseph
    Belani, Chandra Prakash
    Chen, Alice
    Chu, Edward
    Beumer, Jan Hendrik
    Puhalla, Shannon
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [40] Phase I clinical study of cabazitaxel plus prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in a Japanese population.
    Takahashi, Shunji
    Mukai, Hirofumi
    Uemura, Hirotsugu
    Uemura, Hiroji
    Kosaka, Takeo
    Nishiyama, Hiroyuki
    Suzuki, Kazuhiro
    Kakehi, Yoshiyuki
    Okihara, Koji
    Namiki, Shunichi
    Ogawa, Osamu
    Kato, Masashi
    Nakai, Yasutomo
    Ohno, Keiji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345